Form 4 Filing for Urist Marshall - Insider Transaction

This Form 4 filing details a transaction by Urist Marshall, EVP, Research & Investments at Royalty Pharma plc (RPRX). On June 24, 2026, Marshall sold 9,098 Class A Ordinary Shares under a 10b5-1 plan adopted on February 12, 2026. The shares were sold at a weighted average price of $55.1843, with individual transactions ranging from $54.77 to $55.31 per share. Following this sale, Marshall directly owns 9,099 Class A Ordinary Shares. The filing also notes that Marshall and associated entities hold additional interests exchangeable into a significant number of Class A Ordinary Shares and Class E Ordinary Shares, with the latter subject to vesting conditions. The transaction was reported on June 25, 2026.